HUMAN FUSION PROTEINS COMPRISING INTERFERONS AND TARGETED MODIFIED UBIQUITIN PROTEINS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 7, 2014
app pub date -
Jun 15, 2012
filing date -
Jun 15, 2011
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention relates to fusion proteins in which a pharmaceutically active component is fused to an antibody mimetic. The invention specifically concerns fusion proteins comprising interferons or biologically active muteins thereof and modified hetero-dimeric ubiquitin proteins as specific targeting domain. The invention further relates to these fusion proteins for use in medicine, in particular for use in the treatment of cancer or infectious diseases. The invention is further directed to pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with such fusion proteins, and in combination with cancer therapeutic agents. Moreover, the invention relates to a method for the generation of said fusion proteins.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully